HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

irinotecan (Camptosar)

RN given for mono-HCL(S)-isomer; NK012 is a polymeric micellar preparation of SN-38; structure given in first source, 7-ethyl-10-hydroxycamptothecin is active metabolite

Also Known As:

Camptosar; CPT 11; SN 38; 7-ethyl-10-hydroxycamptothecin; ALIRI cpd; CPT-11; Irrinotecan; KN012 compound; NK012 compound; Pfizer brand of irinotecan hydrochloride; SN 38 11; SN-38; SN-38-11; camptothecin-11; irinotecan hydrochloride

Networked: 5122 relevant articles (891 outcomes, 1881 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 60
- Alkaloids: 1065
  - Camptothecin: 1416
    - irinotecan: 5122

Experts

1.	Goldberg, Richard M: 37 articles (04/2015 - 01/2002)
2.	Ohtsu, Atsushi: 32 articles (10/2015 - 01/2002)
3.	Friedman, Henry S: 28 articles (07/2015 - 04/2002)
4.	Yamada, Yasuhide: 27 articles (10/2015 - 01/2002)
5.	Shirao, Kuniaki: 27 articles (04/2014 - 01/2002)
6.	Georgoulias, V: 27 articles (12/2012 - 06/2000)
7.	Falcone, Alfredo: 26 articles (10/2015 - 04/2002)
8.	Boku, Narikazu: 26 articles (10/2015 - 01/2003)
9.	Saijo, Nagahiro: 26 articles (04/2014 - 01/2002)
10.	Kim, Tae Won: 25 articles (05/2015 - 12/2004)

Related Diseases

1.	Colorectal Neoplasms (Colorectal Cancer) 11/21/2015 - "After irinotecan was introduced for the treatment of metastatic colorectal cancer (CRC) at the end of the last century, survival has improved dramatically. " 11/01/2001 - "Weekly CPT-11/5-FU/FA is highly effective in the treatment of patients with metastatic colorectal cancer limited to the liver, even after failure of previous 5-FU/FA. " 01/01/2010 - "To (i) identify the optimal regimen for IFL therapy in terms of irinotecan dosage, and (ii) determine the maximum tolerated dose and efficacy of the modified-IFL regimen in patients with histologically confirmed advanced colorectal cancer. " 08/01/2000 - "Thus, considering other encouraging data from the literature, the CPT-11 + FU-LV combination therapy can be regarded as a new, very effective treatment option for first-line treatment of advanced colorectal cancer patients." 01/01/2008 - "This study aimed to determine the safety and efficacy of high-dose (HD) irinotecan combined with LV5FU2 or simplified LV5FU (LV5FUs) in first-line treatment of metastatic colorectal cancer. "
2.	Neoplasms (Cancer) 08/16/2004 - "The role of the UGT1A1 genotype as a predictor of toxicity in cancer patients receiving irinotecan demands the performance of a randomized trial to ascertain whether genotype-adjusted dosages of the drug can help to establish safe and effective doses not only for patients with the UGT1A1(*)28 homozygous genotype but also for those with the most common UGT1A1 6/6 or 6/7 genotype." 03/01/2007 - "The chemotherapeutic agent irinotecan (IT) is highly effective against several types of cancer, although its use is limited due to severe intestinal toxicity. " 12/01/2014 - "Etirinotecan pegol was eliminated very slowly from the tumor (t 1/2 = 17 days), achieving higher and more sustained tumor exposure when compared with conventional irinotecan. " 04/01/2004 - "HACE with irinotecan induced a complete remission in 44% of the animals and the highest dose reduced the mean tumor cell load by 66% (P < 0.001). " 01/02/2015 - "These nanoassemblies maintain a high (∼47 %) drug loading and exhibit greater drug stability (i.e., resistance to lactone hydrolysis), and consequently greater efficacy against several human cancer cells (HT-29, A549, H460, and H23) in vitro compared with the clinically used prodrug irinotecan. "
3.	Neoplasm Metastasis (Metastasis) 10/01/2010 - "NK012 eradicated the liver metastases and produced a significant longer survival rate than CPT-11 (P = 0.0006). " 11/01/2007 - "HAI (WHF: 1000 mg/m2) plus CPT-11 (100 mg/m2) was effective, and liver metastases showed a significant reduction (PR) on abdominal CT. " 03/01/2003 - "Combination therapy of FR-WBH + CPT-11 resulted in a significantly greater inhibition of axillary lymph node metastasis volume compared to both control and CPT-11 alone (p < 0.02) at day 16. " 11/01/2007 - "HAI plus CPT-11 was effective for a patient of the poor performance status with unresectable liver metastasis." 04/01/2015 - "To compare the feasibility, safety, and efficacy with small and large irinotecan drug-eluting beads (DEBIRI) for treating hepatic colorectal metastases. "
4.	Stomach Neoplasms (Stomach Cancer) 06/01/2007 - "CPT-11 appeared to be highly efficacious when given in combination with CDDP in human gastric cancer cell lines. " 03/01/2011 - "Irinotecan is inactive as a first-line treatment, but plays an important part in gastric cancer treatment." 01/15/2013 - "Overall survival benefits for irinotecan-containing regimens as first-line treatment for advanced gastric cancer: an updated meta-analysis of ten randomized controlled trials." 12/01/2007 - "The combination of 5-FU/LV and irinotecan as first-line treatment was found to be well tolerated and effective in patients with advanced gastric cancer. " 09/01/2005 - "S-1 with CPT-11 can be combined safely without CPT-11 effect on S-1 PK data and holds promise as an effective regimen for advanced gastric cancer."
5.	Colonic Neoplasms (Colon Cancer) 03/01/2004 - "This case suggests the efficacy of home anticancer therapy with PMC and low-dose CPT-11 for highly advanced colon cancer in terms of QOL." 07/01/2009 - "CONCLUSION Irinotecan added to LV5FU2 as adjuvant therapy did not confer a statistically significant improvement in DFS or overall survival in patients with stage III colon cancer compared with LV5FU2 alone." 08/20/2008 - "The efficacy of NGO-PEG-SN38 was far higher than that of irinotecan (CPT-11), a FDA-approved water soluble SN38 prodrug used for the treatment of colon cancer. " 06/01/2005 - "Therefore, CRAd-sCE2/CPT-11 combination therapy appears useful for more effective treatment of colon cancer." 08/01/2004 - "l-LV/5-FU/low-dose CPT-11 seems to be effective for metastatic colon cancer, and safe from the toxicity standpoint."

Related Drugs and Biologics

1.	Fluorouracil (Carac)
2.	oxaliplatin (Eloxatin)
3.	Leucovorin (Folinic Acid)
4.	bevacizumab
5.	irinotecan (Camptosar)
6.	Cisplatin (Platino)
7.	capecitabine (Xeloda)
8.	cetuximab (Erbitux)
9.	gemcitabine
10.	Paclitaxel (Taxol)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Combination Drug Therapy (Combination Chemotherapy)
3.	Heterologous Transplantation (Xenotransplantation)
4.	Radiotherapy
5.	Microspheres (Microsphere)